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Abstract
Background Previous studies have suggested that women
do not accrue equal therapeutic benefit from antiplatelet
medication as compared with men. The physiological
mechanism and clinical implications behind this gender
disparity have yet to be established.
Methods On-treatment platelet reactivity was determined in
717 men and 234 women on dual antiplatelet therapy,
undergoing elective coronary stent implantation. Platelet
function testing was performed using arachidonic acid and
adenosine diphosphate-induced light transmittance aggreg-
ometry (LTA) and the VerifyNow P2Y12 and Aspirin
assays. Also the incidence of all-cause death, non-fatal
acute myocardial infarction, stent thrombosis and ischaemic
stroke was evaluated.
Results Women had higher baseline platelet counts than
men. Women exhibited a higher magnitude of on-aspirin
platelet reactivity using LTA, but not using the VerifyNow
Aspirin assay. The magnitude of on-clopidogrel platelet
reactivity was significantly higher in women as compared
with men with both tests used. The cut-off value to identify
patients at risk as well as the incidence of clinical endpoints
was similar between women and men (16/234[6.8%] vs.
62/717[8.6%], p=0.38).
Conclusion Although the magnitude of platelet reactivity
was higher in women, the absolute difference between
genders was small and both the cut-off value to identify
patients at risk and the incidence of the composite endpoint
were similar between genders. Thus, it is unlikely that the
difference in platelet reactivity accounts for a worse
prognosis in women.
Keywords Gender . Platelet function testing . Clopidogrel .
Aspirin . Antiplatelet therapy
Introduction
Coronary artery disease is the main cause of mortality and
morbidity worldwide [1, 2]. Throughout the last decade
improvements in the diagnosis and treatment of atheroscle-
rosis have caused a marked reduction in the morbidity and
mortality in men, whereas the rate of recurrent athero-
thrombotic events, including cardiovascular death, in
women has increased [3, 4]. Since platelet reactivity plays
a pivotal role in thrombus formation and atherosclerosis,
dual antiplatelet therapy with both aspirin and clopidogrel
has become the cornerstone in the treatment of patients
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undergoing coronary stent implantation and those pre-
senting with acute coronary syndrome (ACS) [5, 6].
However, previous studies have suggested that women do
not accrue equal therapeutic benefit of antithrombotic
therapy [7, 8]. Although multiple contributing factors have
been described, the physiological mechanism behind this
gender disparity remains unclear [9]. Therefore, the aim of
the present study is to compare the magnitude of on-
treatment platelet reactivity between genders in patients on
dual antiplatelet therapy undergoing elective coronary
stenting.
Methods
Population and study design
The POPular study (The Do Platelet Function Assays
Predict Clinical Outcomes in Clopidogrel Pretreated
Patients Undergoing Elective PCI study) was a prospective,
observational study including consecutive patients with
established coronary artery disease scheduled for elective
coronary stent implantation. The entry and exclusion
criteria were described in the original publication. The
POPular study has established that patients exhibiting a
high on-treatment platelet reactivity status were at higher
risk for adverse events post-PCI [10].
In the present sub-analysis all patients were on dual
antiplatelet therapy with adequate clopidogrel treatment
(defined as a maintenance dose of 75 mg daily for >5 days,
a loading dose of 300 mg at least 24 h before PCI or 600 mg at
least 4 h prior to PCI) and low-dose aspirin of 80–100 mg
daily for at least 10 days. Patients were excluded when they
had a whole blood platelet count <150,000/μL or had used
medication (other than aspirin or clopidogrel) known to have
any effect on platelet reactivity (i.e. NSAIDs, dipyramidole,
glycoprotein (GP) IIb/IIIa-inhibitors) within 1 week prior to
inclusion. The study was conducted according to the
principles of the Declaration of Helsinki and the laws and
regulations applicable in the Netherlands. All patients gave
written informed consent.
Clinical endpoint
The clinical endpoint was a combination of all-cause death,
non-fatal myocardial infarction (defined as the occurrence of
ischaemic symptoms as well as a spontaneous troponin T
value or creatine kinase MB greater than the upper limit of
normal), definite stent thrombosis (according to the Academic
Research Consortium criteria) [11] and ischaemic stroke. An
independent committee, blinded for platelet function data,
adjudicated all endpoints through review of source docu-
ments of medical records.
Blood sampling
Prior to heparinisation, whole blood was drawn from the
femoral or radial artery sheath. Blood samples were collected
into Vacuette® tubes (Greiner Bio-one, Frickenhausen,
Germany) containing 3.2% sodium citrate for all platelet
function tests. Blood samples for whole blood count were
drawn into tubes containingK3-EDTA. Platelet function testing
was performed within 2 h after blood withdrawal.
Platelet function testing
Light transmittance aggregometry
Light transmittance aggregometry (LTA) was performed
using an APACT 4004 aggregometer (LABiTec, Arensburg,
Germany) at 37°C. Platelet poor plasma (PPP) was used as
a reference for 100% aggregation and maximal platelet
aggregation (%) was measured in non-adjusted platelet rich
plasma after stimulation with arachidonic acid (AA) in a
final concentration of 0.5 mg/ml to determine on-aspirin
platelet reactivity and adenosine diphosphate (ADP) in a final
concentration of 20 μmol/L to determine on-clopidogrel
platelet reactivity.
VerifyNow® system
The VerifyNow® (Accumetrics, San Diego, USA) is a whole
blood assay designed to measure agonist-induced platelet
aggregation. Aspirin-induced platelet reactivity was measured
with the aspirin assay, which contains arachidonic acid (AA)
(1 mmol/L) and clopidogrel response was measured with the
P2Y12 assay. This assay contains 20 μmol/L ADP to induce
P2Y12-dependent platelet aggregation, and 22 nmol/L pros-
taglandin E1 (PGE1) to minimise the contribution of the
ADP-activated P2Y1 receptor to platelet aggregation. Results
are described as Aspirin Reaction Units (ARU) and P2Y12
Reaction Units (PRU) respectively.
Statistical analysis
Continuous variables were expressed as mean ± SD, unless
otherwise specified, and categorical variables as frequencies
(%). All distributions were checked for normality. Differences
in continuous variables were compared by independent t-test or
Mann–Whitney U test, as appropriate. Dichotomous variables
were compared by chi-square test or Fisher’s exact test.
Covariate adjustment using a propensity score was
performed to reduce confounding factors in the comparison
of the magnitude of platelet reactivity between genders. The
propensity score was defined as the probability of being a
man depending on the baseline characteristics of each
patient and used to account for imbalances in the
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distribution of these characteristics between genders. Prior to
calculation of the propensity score, missing data were imputed
using the program R. The propensity score for each patient
was determined using the following characteristics as
covariates in a logistic regression model: clinical character-
istics (i.e. classic cardiovascular risk factors, previous myo-
cardial infarction (MI), previous percutaneous coronary
intervention (PCI) or previous coronary artery bypass graft
surgery (CABG), renal failure, left ventricular ejection
fraction <45%), co-medication (i.e. use of clopidogrel loading
dose and concomitant use of statins, β-blockers, angiotensin
converting enzyme inhibitors, coumarin derivates, calcium
channel blocker, proton pump inhibitor, upstream GP IIb/IIIa
inhibitor-therapy), laboratory parameters (platelet count, mean
platelet volume, white blood cell count, red blood cell count,
haemoglobin and haematocrit) and procedural risk factors
(i.e. total stent length, number of lesions treated, number of
stents implanted, bifurcation stenting, graft stenting, left
anterior descending coronary artery (LAD), type of stent
implanted (bare-metal stent (BMS), drug-eluting stent (DES)
or both) and minimal stent diameter). Subsequently, linear
regression analysis was performed to compare the magnitude
of platelet reactivity between genders, using the propensity
scores as a covariate.
To evaluate whether the cut-off value to identify patients
at higher risk of atherothrombotic events was similar
between genders, a receiver-operator characteristic (ROC)
curve analysis was calculated for each test in both genders.
The optimal cut-off level was calculated by determining the
smallest distance between the ROC curve and the upper left
corner of the graph. To determine whether the cut-off for
both genders was similar, a heterogeneity index was calculated.
All data were analysed with SPSS version 17.0 (SPSS,
Chicago, IL) and R (version 2.9 http://r-project.org) and a
two-sided p-value <0.05 was considered significant.
Results
Study population
A total of 1069 consecutive patients undergoing elective
PCI with stent implantation were enrolled, of whom 951
were on aspirin >10 days. The latter comprised the present
study population. Due to irregularities in platelet assay
supply, as well as technical failure in a minority of platelet
function tests, not all platelet function assays were
performed in every patient. ADP-induced LTA was per-
formed in 936 patients; AA-induced LTA was performed in
925 patients and the VerifyNow P2Y12 Assay in 940
patients. Since use of the VerifyNow® Aspirin cartridge did
not start until halfway through the POPular study, this assay
was performed in less than half of the population (n=422).
Of the patients, 234 were female (24.6%) and 717 were male
(75.4%). Baseline characteristics are depicted in Table 1.
Women were significantly older than men and were more
likely to have a familial history of coronary artery disease
(CAD). Furthermore, women had a higher platelet count and
a lower haemoglobin value.
Gender-specific differences in platelet reactivity
On-aspirin platelet reactivity
Women exhibited a higher magnitude of on-aspirin platelet
reactivity as compared with men when measured with LTA
(22.4±11.4% vs. 19.8±11.1%, p=0.002). After adjustment
for potential confounders, the difference remained significant
(22.6±0.8% vs. 20.0±0.9%, p=0.002 [mean ± standard error
of the mean (SEM)]). In contrast, women had a similar
magnitude of on-aspirin platelet reactivity using the Verify-
Now® Aspirin Assay (437±4.6 vs. 434±5.6, p=0.06 after
adjustment [mean ± SEM]). (Fig. 1)
On-clopidogrel platelet reactivity
The magnitude of on-clopidogrel platelet reactivity was
significantly higher in women as compared with men when
measured with either LTA (59.6±13.2% vs. 56.9±14.6%, p=
0.01) or the VerifyNow® P2Y12 assay (236±73.9 vs. 198±
73.9, p<0.0001). All differences remained significant after
adjustment for potential confounders in multivariate analysis
(Fig. 2).
Gender-specific differences in clinical outcome
Table 2 summarises 1-year clinical outcome. The occurrence
of the composite endpoint (62/717 [8.6%] in males vs. 16/234
[6.8%] in females, p=0.58), as well as its single components,
was similar between men and women (13/717 [1.8%] men
died vs. 3/234 [1.3%] women).
Gender-specific differences in ROC curve derived
cut-off values
Receiver operator characteristic curve (ROC) analysis dem-
onstrated that the cut-off value to identify patients at higher
risk of atherothrombotic events was not significantly different
between genders (all p-values for heterogeneity > 0.10).
Discussion
Evidence that gender differences play a role in platelet
reactivity was first reported over 30 years ago [12] and this
observation has been confirmed in more recent studies
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[13–16]. Differences in vessel wall biology between men
and women, as well as the direct influence of sex hormones
(oestrogens, progesterone or androgens) on platelets or their
indirect effect on the vasculature, might be underlying
conditions from a biological point of view [4, 17].
Since platelet reactivity plays a pivotal role in thrombus
formation and atherosclerosis, dual antiplatelet therapy with
both aspirin and clopidogrel has become the mainstay in the
treatment of patients undergoing coronary stent implanta-
tion and those presenting with ACS [5, 6, 18, 19]. However,
both drugs result in a wide interindividual range in platelet
inhibition [20, 21] and the association between high on-
treatment platelet reactivity and the occurrence of adverse
events is well established [22–25]. As a consequence,
identification of particular subgroups of patients with high
on-treatment platelet reactivity has gained much attention
[26]. Women have been reported to exhibit a higher
magnitude of both on-aspirin and on-clopidogrel platelet
reactivity more often [13, 27]. However, the cause and
clinical implications of these findings are uncertain.
The results from the present study support previous
findings that women have higher platelet counts [28] and a
higher magnitude of on-treatment platelet reactivity than men
[12, 13, 29]. Women exhibited a higher magnitude of on-
aspirin platelet reactivity as compared with men using light
transmittance aggregometry, but not using the VerifyNow
Table 1 Baseline characteristics of study population
Total population Women Men p-value
(n=951) (n=234) (n=717)
Clinical parameters
Age (years) 64±10.6 67±9.9 63±10.6 <0.001
BMI (kg/m2) 27.3±3.9 27.2±4.7 27.3±3.6 0.607
Current smoker 102 (10.7%) 24 (10.3%) 78 (10.9%) 0.785
Diabetes mellitus 175 (18.4%) 53 (22.6%) 122 (17.0%) 0.053
Hypertension 737 (77.5%) 186 (79.5%) 551 (76.8%) 0.401
Hypercholesterolaemia 769 (80.9%) 189 (80.8%) 580 (81.0%) 0.936
Familial history 580 (61.4%) 171 (74.0%) 409 (57.4%) <0.001
Prior myocardial infarction 432 (45.4%) 94 (40.2%) 338 (47.1%) 0.063
Impaired ejection fraction 133 (14.0%) 35 (15.0%) 98 (13.7%) 0.622
Renal failure 93 (9.8%) 22 (9.4%) 71 (9.9%) 0.809
Medication
Loading dose clopidogrel 489/951 (51.4%) 116 (51.1%) 373 (53.5%) 0.527
Proton pump inhibitor 270 (29.4%) 70 (31.1%) 200 (28.9%) 0.528
Coumarin derivates 24 (2.5%) 2 (0.9%) 21 (3.0%) 0.073
Calcium channel blocker 365 (39.8%) 91 (40.4%) 274 (39.6%) 0.821
Laboratory parameters
Platelet count (× 10^9/L) 273±79 290±78 268±78 <0.001
White blood cell count (× 10^9/L) 7.7±2.6 7.9±3.3 7.7±2.3 0.359
Haemoglobin (mmol/L) 8.5±1.0 7.9±0.8 8.7±0.9 <0.001
Procedural parameters
Mean no. of stents implanted 1.57 1.55±0.9 1.57±0.8 0.15
Minimal stent diameter (mm) 3.1±0.8 3.1±1.4 3.1±0.6 0.67
Total stent length (mm) 28.3±17.1 27.4±17.2 28.6±17.1 0.33
Left anterior descending artery 450/951 (47.3%) 118/234 (50.4%) 448/713 (46.3%) 0.27
Bifurcation lesion 32/951 (3.4%) 9/234 (3.8%) 23/717 (3.2%) 0.64
Drug-eluting stent 604/946 (63.8%) 156/233 (67.0%) 332/717 (62.8%) 0.26
Definitions
Hypertension: Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg
Hypercholesterolaemia: A fasting LDL cholesterol ≥3.4 mmol/L or being on statin therapy at the time of inclusion
Diabetes mellitus: According to the World Health Organization criteria
Family history: One or more first-degree relatives have developed CAD before the age of 55 years (men) or 65 years (women)
Renal insufficiency: Serum creatinine >120 μmol/L
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Aspirin assay. This observation is in line with previous
studies reporting a poor correlation between platelet function
tests [30, 31] and might also be due to a decreased statistical
power, since the VerifyNow Aspirin sample was performed
in only half of the patient population [32]. The magnitude of
on-clopidogrel platelet reactivity was significantly higher in
women as compared with men regardless of the test used. In
addition, the cut-offs to identify patients at higher risk of
atherothrombotic events as well as the prevalence of the
primary endpoint were similar between genders. Thus, the
present study does not support the hypothesis that higher on-
treatment platelet reactivity could account for the gender
differences in clinical outcome and it remains highly
questionable whether this gender-related difference in platelet
reactivity has clinical relevance.
Previously reported in vitro data suggest that although
women have a higher magnitude of platelet reactivity, the
response to aspirin is similar or even larger as compared with
men [13, 33]. This is in line with the observation of a gender-
specific meta-analysis on the role of aspirin in primary
prevention of cardiovascular disease, demonstrating that
aspirin is effective in reducing cardiovascular events in both
women and men [7, 34]. To date, there are few data on the
effects of clopidogrel in women versus men. Whereas
conflicting results have been reported on the association
between on-clopidogrel platelet reactivity and gender [9], a
recent meta-analysis has established that clopidogrel reduces
cardiovascular risk in both men and women [35].
Some issues merit mention. First, the magnitude of
platelet reactivity was determined with a single assessment
Fig. 1 On-aspirin platelet reactivity. The magnitude of on-aspirin platelet reactivity as assessed by AA-induced LTA and the VerifyNow Aspirin
assay prior to (upper part: mean ± SD) and after adjustment for potential confounders (lower part; mean ± SEM)
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while patients were already on antiplatelet therapy. In this
setting, it is impossible to establish whether the difference
in platelet reactivity should be attributed to a higher
intrinsic (baseline) platelet reactivity in women or to less
response. Second, the role of hormonal influences remains
unclear, as menopausal status and menstrual cycle were not
assessed in our study, but the numbers of premenopausal
women in our study are presumably low.
Higher platelet reactivity at baseline among women has
been described previously. Although we support the finding
Fig. 2 On-clopidogrel platelet reactivity. The magnitude of on-aspirin platelet reactivity as assessed by ADP-induced LTA and the VerifyNow
P2Y12 assay prior to (upper part: mean ± SD) and after adjustment for potential confounders (lower part; mean ± SEM)
Table 2 Clinical outcome
MI myocardial infarction, ST
stent thrombosis
Female (n=234) Male (n=717) OR (95 CI) p-value
Death, MI, ST, stroke 16 (6.8%) 62 (8.6%) 0.78 (0.43–1.35) 0.58
Death 3 (1.3%) 13 (1.8%) 0.70 (0.13–2.59) 0.47
MI 11 (4.7%) 43 (6.0%) 0.77 (0.35–1.53) 0.35
ST 1 (0.4%) 8 (1.1%) 0.38 (0.01–2.86) 0.36
Stroke 4 (1.7%) 7 (0.8%) 1.76 (0.37–7.01) 0.38
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that the magnitude of platelet reactivity is higher in women,
the absolute difference between genders is small and both the
cut-off value to identify patients at risk and the incidence of
the composite endpoint was similar between genders. Thus, it
is unlikely that the difference in platelet reactivity accounts for
a worse prognosis in women.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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